Related Experiment Video
Updated: Apr 11, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
c-Met targeting in advanced gastric cancer: An open challenge
Luigi Marano1, Rita Chiari2, Alessio Fabozzi3
1General, Minimally Invasive and Robotic Surgery, Department of Surgery, "San Matteo degli Infermi" Hospital, ASL Umbria 2, 06049 Spoleto, Italy.
Abstract:
Despite significant improvements in systemic chemotherapy over the last two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma (GC) remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. High-quality research and advances in technology have contributed to the elucidation of molecular pathways underlying disease progression and have stimulated many clinical studies testing target therapies in an advanced disease setting. In particular, strong preclinical evidence for the aberrant activation of the HGF/c-Met signaling pathways in GC cancers exists. This review will cover the c-Met pathway, the mechanisms of c-Met activation and the different strategies of its inhibition. Next, we will focus on the current state of the art in the clinical evaluation of c-Met-targeted therapies and the description of ongoing randomized trials with the idea that in this disease, high quality translational research to identify and validate biomarkers is a priority task.
Insights
Targeting the HGF/c-Met pathway offers a promising strategy for advanced gastric cancer (GC). This review explores c-Met inhibition and its clinical evaluation for improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Advanced gastric and gastroesophageal junction adenocarcinoma (GC) has a poor prognosis despite chemotherapy advancements.
- Tumor molecular heterogeneity necessitates personalized targeted therapies based on oncogenic pathways.
- The HGF/c-Met signaling pathway is frequently aberrantly activated in GC.
Purpose of the Study:
- To review the c-Met pathway, its activation mechanisms, and inhibition strategies in GC.
- To summarize the clinical evaluation of c-Met-targeted therapies for advanced GC.
- To highlight the importance of biomarker research in developing targeted therapies for GC.
Main Methods:
- Literature review of preclinical and clinical studies on HGF/c-Met signaling in GC.
- Analysis of current clinical trial data for c-Met inhibitors in advanced GC.
- Discussion of ongoing randomized trials and biomarker validation strategies.
Main Results:
- Preclinical data strongly support aberrant HGF/c-Met pathway activation in GC.
- Clinical evaluation of c-Met-targeted therapies is ongoing, with several agents under investigation.
- Translational research for biomarker identification and validation is crucial for treatment success.
Conclusions:
- Targeting the HGF/c-Met pathway represents a rational therapeutic strategy for advanced GC.
- Further clinical evaluation and biomarker-driven approaches are essential to optimize c-Met inhibitor efficacy.
- Personalized medicine through molecular classification and targeted therapies holds promise for improving GC patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...